A comparative survival analysis indicated that CRC patients with genetic alterations of c-MET/EGFR exhibited shorter overall survival (OS), DFS, and progressive-free survival than cohorts without c-MET/EGFR alterations (Figure 3D). Here, MET is linked to colorectal carcinoma.